Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. (CERE) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cere · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cerevel Therapeutics Holdings, Inc. (CERE) measures how much investors pay for each dollar of the company's trailing earnings. CERE's current PE ratio of N/A is calculated by dividing its stock price of $44.96 by its TTM earnings per share of -$2.67.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2012 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cerevel Therapeutics Holdings, Inc.You CERE | $8.2B | N/A | — | -$2.67 |
 Blueprint Medicines Corporation BPMC | $8.4B | N/A | — | -$1.07 |
 ImmunoGen, Inc. IMGN | $8.7B | N/A | — | -$0.88 |
 IVERIC bio, Inc. ISEE | $5.5B | N/A | — | -$1.45 |
 Mirati Therapeutics, Inc. MRTX | $4.1B | N/A | — | -$13.18 |
 Oak Street Health, Inc. OSH | $9.5B | N/A | — | -$2.21 |
 Reata Pharmaceuticals, Inc. RETA | $6.6B | N/A | — | -$8.59 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-2.67 | — | |
2022-12-31 FY2022 | — | $-2.32 | — | |
2021-12-31 FY2021 | — | $-1.63 | — | |
2020-12-31 FY2020 | — | $-1.29 | — | |
2019-12-31 FY2019 | — | $-1.01 | — | |
2018-12-31 FY2018 | — | $-6.56 | — | |
2015-08-31 FY2015 | — | $-1.98 | — | |
2014-08-31 FY2014 | — | $-2.06 | — | |
2013-08-31 FY2013 | — | $-2.28 | — | |
2012-08-31 FY2012 | — | $-2.07 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cerevel Therapeutics Holdings, Inc. (CERE) measures how much investors pay for each dollar of the company's trailing earnings. CERE's current PE ratio of N/A is calculated by dividing its stock price of $44.96 by its TTM earnings per share of -$2.67.
Frequently asked questions
CERE pe ratio · 6 questionsCERE's current PE ratio is N/A as of 2026-06-09, based on a stock price of $44.96 and TTM EPS of -$2.67. Data sourced from Financial Modeling Prep via CERE's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cerevel Therapeutics Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09